Last updated on Thursday, 29 March 2018

Southwest Women's Oncology

Trial #TypeStudy StatusStatus DateTitle
RTOG 0724/GOG-0724GYN Cervical AdjuvantOpen Active2015-10-30RTOG 0724/GOG-0724 : Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
GOG 0263GYN Cervical AdjuvantOpen Active2010-12-02GOG 0263: Randomized Phase III Clinical Trial of Adjuvant Radiation versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy
GOG 0274GYN Cervical AdvancedOpen Active2012-07-30GOG 0274: A Phase III Trial of Adjuvant Chemotherapy Following Chemo-radiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemo-radiation Alone: The OUTBACK Trial
NRG Oncology NRG-GY002GYN Cervical AdvancedOpen Active2016-05-03NRG Oncology NRG-GY002: A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer
GOG-0286BGYN Endometrial AdvancedOpen Active2017-01-10GOG 0286B: A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
NRG Oncology NRG-GY005GYN OtherOpen Active2017-04-28NRG Oncology NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
NRG Oncology NRG-GY004GYN Ovarian AdjuvantOpen Active2017-04-28NRG Oncology NRG-GY004: A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer
Pharm 0403GYN Ovarian AdvancedOpen Active2017-05-26ImmunoGen 0403: FORWARD1: A Randomized, Open Label Phase 2 Study to Evaluate the
Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator
GOG 0264GYN Ovarian AdvancedOpen Active2011-04-21GOG 0264: A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary
GOG 0213GYN Ovarian AdvancedOpen Active2009-09-01GOG 0213: A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel(or Gemcitabine) Alone or in Combination with Bevacizumab(NSC #704865, IND #113912)Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
INST CR1303GYN Ovarian AdvancedOpen Active2013-07-30(IRB EXEMPT) INST CR1303: Magnesium Levels in Ovarian Cancer Patients Undergoing Taxol and Platinum Based Chemotherapy and the Correlation with Neuropsychologic Outcomes via FACT Quality of Life Scores
GOG 0238GYN Uterine AdvancedOpen Active2015-08-24GOG 0238: A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
ECOG-ACRIN EAY131-AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-A: MATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
ECOG-ACRIN EAY131-Z1BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1B: MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC
ECOG-ACRIN EAY131-MMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-M: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations
ECOG-ACRIN EAY131-S1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
ECOG-ACRIN EAY131-C1Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C1: MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification
ECOG-ACRIN EAY131-S2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-S2: Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations
ECOG-ACRIN EAY131-JMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification
ECOG-ACRIN EAY131-Z1EMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
ECOG-ACRIN EAY131-Z1AMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1A: MATCH Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations
ECOG-ACRIN EAY131-UMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-U: MATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
ECOG-ACRIN EAY131-Z1IMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1I: Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations
ECOG-ACRIN EAY131-Z1DMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Z1D: MATCH Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)
ECOG-ACRIN EAY131-YMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-Y: MATCH Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations
ECOG-ACRIN EAY131-LMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-L: Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations
ECOG-ACRIN EAY131-C2Multiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-C2: MATCH Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion
ECOG-ACRIN EAY131-TMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-T: 1
Molecular Analysis for Therapy Choice (MATCH)
MATCH Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations
ECOG-ACRIN EAY131-BMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-B: MATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
ECOG-ACRIN EAY131-EMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-E: MATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
ECOG-ACRIN EAY131-XMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-X: MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations
ECOG-ACRIN EAY131-VMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-V: MATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
ECOG-ACRIN EAY131-WMultiple SitesOpen Active2016-11-05ECOG-ACRIN EAY131-W: MATCH Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway
ECOG-ACRIN EAY131-Z1CMultiple SitesOpen Active2017-03-11ECOG-ACRIN EAY131-Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
SWOG S1404Skin Melanoma AdvancedOpen Active2017-03-01SWOG S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475
(PEMBROLIZUMAB) in Patients with High Risk Resected Melanoma
ECOG-ACRIN EAY131-GSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-G: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
ECOG-ACRIN EAY131-FSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-F: Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
ECOG-ACRIN EAY131Solid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131: Molecular Analysis for Therapy Choice (MATCH)
ECOG-ACRIN EAY131-HSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-H: Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
ECOG-ACRIN EAY131-RSolid Tumors OtherOpen Active2016-11-05ECOG-ACRIN EAY131-R: Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
National Cancer Prevention DCP-001SupportiveOpen Active2016-08-17Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
GOG 0225SupportiveOpen Active2016-11-10GOG 0225: Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?